A pilot randomized controlled trial of major ozone autohemotherapy for patients with post-acute sequelae of COVID-19
He Y, Liu X, Zha S, et al. International Immunopharmacology, 2024.
- Study type
- Randomized controlled trial
- People studied
- 73 people
- Population
- Patients with post-acute sequelae of COVID-19
- Published
- 2024, International Immunopharmacology
- Identifiers
- PMID 39018686, DOI 10.1016/j.intimp.2024.112673
What the authors reported
In a pilot RCT, 35 patients given major ozone autohemotherapy plus conventional therapy had a higher symptom-score response rate (71%) than 38 given conventional therapy alone (45%), with better walk distance and lung function measures.
What limits this result
The authors describe it as a pilot needing validation; tests major autohemotherapy, not EBO2, and the abstract does not describe blinding of outcome assessment.
Other ozone methods, such as major autohemotherapy, that clinics cite in support of EBO2. A result for one method does not transfer automatically to another. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
EBO2 (EBOO) for Long COVID: What Has Been Studied
What NIH RECOVER, FDA enforcement action, and small ozone autohemotherapy trials actually show about EBO2 (also called EBOO) and long COVID symptoms.